[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-menopause\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-menopause":197},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,84,116,143,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100641575","veda-study-dhea-vs-estradiol-100641575",false,"NCT07574216","VEDA Study (DHEA vs Estradiol)","The Use of Vaginal Estrogen vs DHEA in Perimenopausal and Menopausal Women","Inclusion Criteria:\n\n* Peri- or post-menopausal status\n* Presence of any genitourinary or vaginal symptom (e.g., dryness, itching, discomfort, dyspareunia)\n* Willingness and ability to use vaginal therapy\n* Ability to provide informed consent\n* English speaker\n* Ages 40-90\n\nExclusion Criteria:\n\n* Use of systemic hormone therapy within the last 6 months\n* Gynecologic malignancy\n* Known allergy to study medications\n* Active vaginal infection at enrollment\n* Prior pelvic radiation",true,"FEMALE","40 Years","90 Years",{"count":21,"type":22},324,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is being done to compare two vaginal treatments, vaginal estrogen and vaginal DHEA, that are used to treat vaginal and urinary symptoms related to menopause. These symptoms may include vaginal dryness, discomfort, painful intercourse, or urinary problems and can affect quality of life and sexual health. Women who choose to participate will be randomly assigned to use one of the two treatments for a set period of time. Participants will complete questionnaires about their symptoms and sexual health and have simple vaginal testing at the beginning and end of the study. The goal of this research is to better understand how these treatments affect vaginal health and sexual function so healthcare providers can make informed treatment decisions and improve care for postmenopausal women.",[28,29,30,31,32,33],"Post-menopause","Pre-menopause","Sexual Function","Menopause","Vaginal Dryness","Painful Intercourse",[35,36],"DHEA","vaginal estrogen","NOT_YET_RECRUITING","2026-06-15",{"date":40,"type":41},"2026-06-17","ACTUAL",{"date":43,"type":22},"2026-06-01",{"date":45,"type":22},"2031-12-31",{"name":47,"class":48},"University of Arizona","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100598718","chrono-restricted-diet-and-physical-activity-as-a-new-preventive-strategy-for-sarcopenia-in-postmenopausal-women-with-obesity-and-type-2-diabetes-100598718","NCT07075133","Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes","TIMEDIAB","Inclusion Criteria:\n\n* Post-menopausal women (amenorrhea for at least 12 months, confirmed by gonadotrophins measures)\n* Age range 45-70 years\n* T2DM diagnosed for more than 1 year\n* Subjects with T2DM treated with lifestyle control alone or associated with metformine ± DPP4 inhibitors\n* Ability to sign written informed consent before any study-specific procedure\n* Subject considered as reliable and capable of adhering to protocol\n* Subjects with Body Mass Index (BMI)≥ 30 kg\u002Fm²\n* Baseline eating period ≥ 14 h per day (as estimated by 95% eating interval)\n\nExclusion Criteria:\n\n* Subjects on T2DM injectable medication or drugs able to induce hypoglycemia (glinides, sulfonylurea)\n* Subjects with HbA1c \\> 8%\n* Subjects with any of the following medical conditions:\n\n  * Congestive cardiac failure\n  * Stage 4 chronic kidney disease (i.e. eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2)\n  * Liver cirrhosis or chronic liver disease\n  * Any medical condition that in the opinion of the investigator could jeopardize or compromise the subject's ability to participate in the study\n* Subjects with previous or present history of serious eating disorder\n* Subjects not able to understand the informed consent form or fasting diary instructions\n* Subjects currently participating or has participated in another study of an investigational medication or an investigational medical device within the last 30 days\n* Women with menopause hormone replacement therapy","ALL","45 Years","70 Years",{"count":60,"type":22},45,[25],"The aim of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on muscle function as primary endpoint, and glucose homeostasis as secondary endpoint",[64,65,66,67,68],"Obesity","Sarcopenia","Post Menopause","Type 2 Diabetes","Circadian Clock",[70,71,72,73,64,31,74],"Timing of eating","Timing of exercise","Muscle Function","Metabolic Health","women","2026-05-28",{"date":43,"type":41},{"date":78,"type":22},"2026-09-15",{"date":80,"type":22},"2029-07-15",{"name":82,"class":48},"University Hospital, Toulouse",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":58,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":94,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":83},"100636991","beetroot-juice-a-natural-aid-for-boosting-the-health-benefits-of-exercise-in-post-menopausal-women-100636991","NCT07572877","Beetroot Juice: a Natural Aid for Boosting the Health Benefits of Exercise in Post-menopausal Women?","BEETBOOST","Inclusion Criteria:\n\n* Self-reported biological female and postmenopausal (≥12 months of amenorrhea)\n* Aged 50-70 years\n* Body mass index (BMI) 25-39.9 kg\u002Fm²\n* No contraindications to exercise\n* Physically inactive (\\\u003C150 minutes\u002Fweek of moderate-intensity activity)\n* Able to walk on a treadmill and ambulate without limitations\n* Adequate proficiency in Norwegian to complete questionnaires\n* Willingness and ability to comply with the study schedule and visits\n\nExclusion Criteria:\n\n* Known allergy to nitrates or beetroot juice\n* Current smoker or use of nicotine\u002Ftobacco products\n* Resting blood pressure \\\u003C90\u002F60 mmHg\n* Hypertension greater than stage II (≥160\u002F100 mmHg, ESH criteria)\n* Use of prescription medications affecting heart rate (e.g., systemic β-adrenergic blockers) or nitrate availability (e.g., nitrates, proton pump inhibitors)\n* History of cardiovascular disease (e.g., myocardial infarction, stroke, ischemic heart disease, peripheral artery disease, valvular disease, or aortic aneurysm)\n* Symptoms suggestive of heart disease (e.g., chest pain or dyspnea)\n* Major metabolic disease (e.g., type 1 or type 2 diabetes) or thyroid disorders\n* Recent cancer diagnosis or treatment (within the past 5 years)\n* Significant orthopedic limitations or other contraindications to exercise\n* Diagnosed cognitive impairment\n* Planned travel or elective surgery that would interfere with adherence to the intervention\n* Psychological or social factors that may interfere with study participation\n* Residing beyond a reasonable distance from the study site (logistical constraints)","50 Years",{"count":93,"type":22},60,[25],"Menopause and ageing bring several changes to women's health, partly due to a decline in the hormone estrogen. This reduction affects multiple systems in the body, including muscles and bones, and also influences the production of nitric oxide, a molecule that plays a key role in regulating blood flow and blood pressure. An reduced ability to produce nitric oxide is associated with higher blood pressure and an increased risk of cardiovascular and metabolic diseases.\n\nMany women also experience lower levels of physical activity and changes in body composition during midlife, such as increased body fat and reduced muscle mass and strength, which may further decrease exercise capacity.\n\nThis PhD project investigates whether a simple, natural strategy, combining exercise with beetroot juice, can help postmenopausal women achieve greater benefits from exercise. Beetroot juice is naturally rich in nitrates, which the body can convert into nitric oxide, thereby enhancing blood flow. Exercise itself also stimulates nitric oxide production, and together these approaches may have additive or even synergistic effects.\n\nThe study examines whether consuming beetroot juice before exercise can enhance training adaptations and health outcomes in postmenopausal women. Key outcomes include cardiovascular function, body composition, musculoskeletal function, and aerobic capacity.\n\nSome evidence suggests that beetroot juice may amplify the body's response to exercise, which could be particularly beneficial for postmenopausal women, who often face greater barriers to physical activity. By exploring this combined approach, the project aims to evaluate a safe, non-pharmacological strategy to improve physical function and overall health in women after menopause.",[28],[98,99,100,101,102,103,104,105],"exercise","beetroot juice","strength training","endurance training","cardiometabolic health","muscleskeletal function","exercise performance","body composition","RECRUITING","2026-05-11",{"date":109,"type":41},"2026-05-13",{"date":111,"type":41},"2026-02-11",{"date":113,"type":22},"2033-01-01",{"name":115,"class":48},"Western Norway University of Applied Sciences",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":130,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":83},"100623880","effects-of-amylopectin-chromium-blend-on-whole-body-protein-kinetics-and-glucose-in-peripost-menopausal-women-100623880","NCT07402382","Effects of Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose in Peri\u002FPost-Menopausal Women","Effects of an Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose Control in Peri\u002FPost-Menopausal Women","Inclusion Criteria:•\n\nWomen aged 40-65 years who meet either of the following menstrual-history criteria:\n\n* ≥ 60 days but \\\u003C 12 months of amenorrhea (late perimenopause)\n* Women with ≥ 12 months of spontaneous amenorrhea (post-menopausal)\n\n  * No more than 3 days per week of structured physical activity\n  * Provide voluntary signed and dated informed consent.\n  * Be in good health and able to participate in an exercise bout as determined by assessment, medical history, and routine blood chemistries.\n  * Between the of 40 and 65 years of age (inclusive).\n  * Body Mass Index of 18.5-34.9 (inclusive).\n  * Body weight of at least 110 pounds.\n  * Normotensive (seated, resting systolic blood pressure \\\u003C140 mm Hg and diastolic blood pressure \\\u003C 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5-minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.\n  * Normal supine, resting heart rate (\\\u003C90 per minute).\n  * Subject agrees to follow standardized controlled diet for 3 days and maintain existing dietary patterns on other days throughout the study period.\n  * Subject is willing and able to comply with the study protocol.\n  * Able to provide an adequate blood draw.\n  * If a dietary supplement was initiated within the past month, the participant is willing to discontinue supplement use followed by a 2-week washout prior to participation in the study. Note: A generic multivitamin is allowed.\n  * Refrain from caffeine, exercise, and alcohol for 24 hours prior, and fast for 10 hours prior to each visit.\n\nExclusion Criteria:\n\n* Current use of any dietary ingredient that impacts glucose control or insulin sensitivity.\n* Current vegans or vegetarians.\n* Intolerance to dairy foods\u002Fdrinks.\n* Smokes more than 10 cigarettes per day or uses other nicotine products (i.e. vape, patch) that deliver a similar amount of nicotine.\n* History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).\n* Prior gastrointestinal bypass surgery (Lapband, etc.).\n* Individuals using any kind of GLP-1 medications.\n* Other known gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism, e.g. electrolyte abnormalities, diabetes, thyroid disease, adrenal disease, hypogonadism, short bowel syndrome, diarrheal illnesses, history of colon resection, gastric ulcer, reflux disease, gastroparesis, Inborn-Errors-of-Metabolism (such as PKU).\n* Individuals who have gained or lost more than 10 pounds within the last 30 days.\n* Individuals who are cognitively impaired and\u002For who are unable to give informed consent.\n* Chronic medically diagnosed inflammatory condition or disease (e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV\u002FAIDS, etc.).\n* Medical history of hepatorenal, musculoskeletal, autoimmune, or neurologic disease.\n* Known sensitivity to any ingredient in the test formulations as listed in the Certificates-of-Analysis.\n* Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoint or place the subject at increased risk of harm if they were to participate.",{"count":93,"type":22},[25],"The goal of this study is to better understand how an amylopectin chromium blend may influence whole body protein balance in women during midlife, when hormonal changes can adversely affect protein metabolism and muscle maintenance. Continuous glucose monitoring will also be used to assess glycemic control over a 24-hour period.\n\nThe main questions the study aims to answer are:\n\n* Does the use of an amylopectin chromium blend in peri- and post-menopausal women help to support positive protein balance\n* Can the affect be achieved using a concentrated dose\n\nResearchers will compare the nutritional supplement to a placebo (amylopectin alone) to see if the amylopectin chromium blend can promote positive protein balance. A concentrated dose of the supplement will also be evaluated for comparative effectiveness.\n\nParticipants will:\n\n* Consume the nutritional supplement (standard or concentrated dose) or placebo acutely after a short resistance exercise bout\n* Complete four in-person visits, including the single-day intervention\n\nResults from this research may help guide future nutritional strategies to support healthy aging, muscle function, and overall metabolic health.",[127,128,129,28],"Glucose Monitoring, Continuous","Whole Body Protein Metabolism","Peri-menopausal Women",[131,132],"Glucose","protein metabolism","2026-04-06",{"date":135,"type":41},"2026-04-13",{"date":137,"type":41},"2025-11-01",{"date":139,"type":22},"2026-09-30",{"name":141,"class":142},"Nutrition 21, Inc.","INDUSTRY",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100453706","aerobic-vs-resistance-exercise-in-post-menopausal-women-with-type-1-diabetes-100453706","NCT05188027","Aerobic vs Resistance Exercise in Post-menopausal Women With Type 1 Diabetes","Acute Glycemic Effects of Aerobic and Resistance Exercise in Post-menopausal Women With Type 1 Diabetes","Inclusion Criteria:\n\n* type 1 diabetes, diagnosed for at least one year\n* post-menopause (at least one year since last menstrual period), or have had a hysterectomy and bilateral salpingo oophorectomy\n* able to perform aerobic and resistance exercise\n* able to visit the lab in Edmonton, Alberta (University of Alberta)\n\nExclusion Criteria:\n\n* HbA1c \\> 9.9 %\n* frequent and unpredictable hypoglycemia\n* change in insulin management strategy within the last 2 months\n* blood pressure \\> 140 \u002F 95\n* severe peripheral neuropathy\n* history of cardiovascular disease\n* musculoskeletal injuries interfering with exercise performance\n* use of medications (other than insulin) that affect glucose metabolism\n* BMI \\> 30 kg\u002Fm2\n* smoking\n* moderate to high alcohol intake (\\> 2 drinks\u002Fday)","75 Years",{"count":152,"type":22},20,[25],"Participants will be asked to wear a continuous glucose monitor for at least three days on three separate occasions. One testing session will be a no-exercise resting control session (90 minutes). One will be a moderate aerobic exercise session (30 minutes of exercise, 60 minutes of recovery), and the third will be a moderate weight-lifting session (\\~30 minutes of exercise, 60 minutes of recovery).The investigators will measure changes in blood glucose during exercise by drawing blood during and after exercise. Post-exercise glucose trends will be examined using continuous glucose monitoring.",[156,28],"Type 1 Diabetes",[158,159],"Exercise","Physical activity","2026-03-12",{"date":162,"type":41},"2026-03-16",{"date":164,"type":41},"2021-11-16",{"date":166,"type":22},"2027-03-30",{"name":168,"class":48},"University of Alberta",2,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":196},"100470115","mental-stress-reactivity-in-women-with-cmd-100470115","NCT05401630","Mental Stress Reactivity in Women With CMD","Mental Stress Reactivity in Women With Coronary Microvascular Dysfunction","CMD Group\n\nInclusion Criteria:\n\n* Symptomatic postmenopausal women with chest pain\n* age≥45 years old\n* willing to undergo cardiac MIBG scan\n* willing to undergo mental stress testing\n* competent to give informed consent\n\nExclusion Criteria:\n\n* Significant epicardial stenosis (defined by coronary stenosis ≥ 70% in any epicardial coronary artery or hemodynamically significant stenosis determined by fractional flow reserve)\n* Left ventricular systolic dysfunction (ejection fraction ≤ 50%)\n* Heart failure with a preserved ejection fraction\n* Significant anemia or blood dyscrasia\n* Severe uncontrolled hypertension \\>180\u002F100\n* Unable to lie flat for mental stress testing\n* Pre-menopausal\n* Pregnant\n* Pericarditis\u002Fmyocarditis\n* History of percutaneous coronary intervention\n* Coronary artery bypass grafting\n* Acute myocardial infarction\u002Facute coronary syndrome\u002Funstable angina within 1 month\n* Significant valvular disease, including aortic or mitral stenosis\n* Sinus node dysfunction\u002Fpacemaker, 2nd or 3rd-degree atrioventricular block\n* Severe lung, renal, liver, or psychiatric illness\n* Current neoplasm\n* History of substance abuse\n* Acute illness such as infection in the previous 4 weeks\n* Life-expectancy less than 2 years\n* Unable to safely withdraw medications for mental stress testing\n* Significant psychiatric illness that precludes safe participation in the study\n* Conditions that preclude accurate or safe testing and patient refusal\n* Unable to consent\n\nObstructive CAD (oCAD) Group\n\nInclusion Criteria:\n\n* Symptomatic postmenopausal women with chest pain who have obstructive CAD in at least one epicardial coronary artery\n* willing to undergo cardiac MIBG scan\n* willing to undergo mental stress testing\n* competent to give informed consent\n\nExclusion Criteria:\n\n* Significant epicardial stenosis (defined by coronary stenosis ≥ 70% in any epicardial coronary artery or hemodynamically significant stenosis determined by fractional flow reserve)\n* Left ventricular systolic dysfunction (ejection fraction ≤ 50%)\n* Heart failure with a preserved ejection fraction\n* Significant anemia or blood dyscrasia\n* Severe uncontrolled hypertension \\>180\u002F100\n* Unable to lie flat for mental stress testing\n* Pre-menopausal\n* Pregnant\n* Pericarditis\u002Fmyocarditis\n* History of percutaneous coronary intervention\n* Coronary artery bypass grafting\n* Acute myocardial infarction\u002Facute coronary syndrome\u002Funstable angina within 1 month\n* Significant valvular disease, including aortic or mitral stenosis\n* Sinus node dysfunction\u002Fpacemaker, 2nd or 3rd-degree atrioventricular block\n* Severe lung, renal, liver, or psychiatric illness\n* Current neoplasm\n* History of substance abuse\n* Acute illness such as infection in the previous 4 weeks\n* Life expectancy is less than 2 years\n* Unable to safely withdraw medications for mental stress testing\n* Significant psychiatric illness that precludes safe participation in the study\n* Conditions that preclude accurate or safe testing and patient refusal\n* Unable to consent\n\nAsymptomatic Control Group\n\nInclusion Criteria:\n\n* Asymptomatic postmenopausal women, age ≥ 45 years old\n* Healthy volunteer with no cardiac risk factors\n* No history or diagnosis of heart disease\n* Not on any cardiac medications\n* Normal maximal exercise treadmill stress testing (ETT)\n* Fully understanding and willing to undergo mental stress testing\n* Willing to sign the informed consent\n\nExclusion Criteria:\n\n* Significant epicardial stenosis (defined by coronary stenosis ≥ 70% in any epicardial coronary artery or hemodynamically significant stenosis determined by fractional flow reserve)\n* Left ventricular systolic dysfunction (ejection fraction ≤ 50%)\n* Heart failure with a preserved ejection fraction\n* Significant anemia or blood dyscrasia\n* Severe uncontrolled hypertension \\>180\u002F100\n* Unable to lie flat for mental stress testing\n* Pre-menopausal\n* Pregnant\n* Pericarditis\u002Fmyocarditis\n* History of percutaneous coronary intervention\n* Coronary artery bypass grafting\n* Acute myocardial infarction\u002Facute coronary syndrome\u002Funstable angina within 1 month\n* Significant valvular disease, including aortic or mitral stenosis\n* Sinus node dysfunction\u002Fpacemaker, 2nd or 3rd-degree atrioventricular block\n* Severe lung, renal, liver, or psychiatric illness\n* Current neoplasm\n* History of substance abuse\n* Acute illness such as infection in the previous 4 weeks\n* Life expectancy is less than 2 years\n* Unable to safely withdraw medications for mental stress testing\n* Significant psychiatric illness that precludes safe participation in the study\n* Orthopedic limitation that will prevent ETT\n* LDL \\>120 mg\u002FdL\n* Fasting blood glucose \\>95 mg\u002FdL\n* Hypertension, defined as resting BP \\>120\u002F80\n* Diabetes\n* Hyperlipidemia\n* Smoking\n* Conditions that preclude accurate or safe testing and patient refusal\n* Unable to consent",{"count":178,"type":22},150,[25],"Coronary Microvascular Dysfunction (CMD) occurs when there are problems in the small blood vessels\u002Farteries of the heart, resulting in persistent chest pain that affects women.\n\nThere are an estimated 3 million women in the US with CMD and about 100,000 new cases annually. This research will investigate whether the stress response physiology and autonomic function in response to mental stress are different in women with CMD compared to other groups. The autonomic nervous system (ANS) controls normally involuntary activities, such as heart rate, respiration (breathing), body temperature, blood pressure, and urinary function. This study will also examine how chronic and daily life mental stress affects the heart and blood vessels.\n\nParticipants from this study will be recruited mainly from Emory Healthcare-associated hospitals, the Emory Heart Disease Center for Prevention, and Emory Healthcare outpatient cardiology clinics. Participants will have physical exams, blood tests, stress tests, exercise tests, surveys, questionnaires, and images taken of their hearts and blood vessels. They will be asked to take home devices to monitor their autonomic function, sleep, and track their mood, stress level, and symptoms for one week. Data and specimens will be saved for future research.",[28],[183,184,185,186],"Microvascular","Sympathetic activity","Mental Stress","Angina","2026-01-27",{"date":189,"type":41},"2026-01-29",{"date":191,"type":41},"2022-07-19",{"date":193,"type":22},"2026-12-31",{"name":195,"class":48},"Emory University",4,"Post-Menopause"]